Compare NSPR & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSPR | MNOV |
|---|---|---|
| Founded | 2005 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.8M | 72.7M |
| IPO Year | N/A | 2005 |
| Metric | NSPR | MNOV |
|---|---|---|
| Price | $1.95 | $1.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $4.00 | ★ $7.00 |
| AVG Volume (30 Days) | 84.2K | ★ 91.6K |
| Earning Date | 11-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,779,000.00 | $257,917.00 |
| Revenue This Year | $22.76 | N/A |
| Revenue Next Year | $75.45 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.04 | N/A |
| 52 Week Low | $1.59 | $1.13 |
| 52 Week High | $3.80 | $2.24 |
| Indicator | NSPR | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 48.95 | 44.81 |
| Support Level | $1.88 | $1.48 |
| Resistance Level | $2.07 | $1.51 |
| Average True Range (ATR) | 0.12 | 0.05 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 62.89 | 7.69 |
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.